Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025

Executive Summary

Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.

You may also be interested in...



With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway

Johnson & Johnson investors are turning attention to 2023, when the company's top-selling drug is set to face biosimilar competition in the US for the first time.

Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space

CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.

Ipsen To Exit Consumer Health And Focus On Specialty Pharma

The French group is sharpening its focus on specialty care  in oncology, rare disease and neuroscience, so is looking to divest its consumer health division to Mayoly Spindler.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel